ID: ALA383687

Max Phase: Preclinical

Molecular Formula: C26H32N4O7

Molecular Weight: 512.56

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCC[C@H](NC(=O)O[C@@H]1C(=O)N(C(=O)c2ccno2)CC1(C)C)C(=O)C(=O)N[C@H](C)c1ccccc1

Standard InChI:  InChI=1S/C26H32N4O7/c1-5-6-12-18(20(31)22(32)28-16(2)17-10-8-7-9-11-17)29-25(35)36-21-24(34)30(15-26(21,3)4)23(33)19-13-14-27-37-19/h7-11,13-14,16,18,21H,5-6,12,15H2,1-4H3,(H,28,32)(H,29,35)/t16-,18+,21-/m1/s1

Standard InChI Key:  NGSRRUWCODUIPK-PLMTUMEDSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 512.56

Molecular Weight (Monoisotopic): 512.2271

AlogP: 2.78

#Rotatable Bonds: 10

Polar Surface Area: 147.91

Molecular Species: NEUTRAL

HBA: 8

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 11

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 12.20

CX Basic pKa:

CX LogP: 3.21

CX LogD: 3.21

Aromatic Rings: 2

Heavy Atoms: 37

QED Weighted: 0.36

Np Likeness Score: -0.50

References

1. Barrett DG, Catalano JG, Deaton DN, Hassell AM, Long ST, Miller AB, Miller LR, Ray JA, Samano V, Shewchuk LM, Wells-Knecht KJ, Willard DH, Wright LL..  (2006)  Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors.,  16  (6): [PMID:16376075] [10.1016/j.bmcl.2005.11.101]

Source

Source(1):

• Scientific Literature